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ABSTRACT
The market for patient data management products (a subset of Hewlett-Packard's Patient Monitoring
Division's product set) is changing. These products have traditionally been made with custom hardware
and embedded software, and manufactured in house, that is, by HP. However, for these products, HP has
made a strategic decision to build them using industry standard hardware components whenever possible.
This is, in effect, outsourcing the manufacture of hardware components. HP's medical information
management tools are largely computational, so HP can enjoy much faster increases in capability with
minimal product redesign by using industry standard computation and data handling hardware. HP sees that
to stick with custom-designed and built hardware would leave itself at a disadvantage relative to its
competition and the expectations of the marketplace.
Like many other companies and HP divisions, PMD has been evaluating its supply chains, considering
where it might increase or decrease the level of outsourcing. PMD has already taken a step away from
vertical integration by using industry standard hardware as a base for many of its systems. From here, PMD
must decide at what other points in the delivery process to outsource processes, as well as how to transition
from its current processes to the new structure.
The goal of this thesis is to recommend supply chain improvements, recognizing future market trends and
where future value will exist. It will be contended that value (and therefore lucrative margins) will be
created in software design, as well as in process design for medical software implementation; hardware
handling will not carry value once current technical barriers are overcome. This understanding should
guide HP's sourcing decisions. The thesis will go on to recommend and justify specific sourcing changes
for PMD.
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Chapter One : Introduction
1 Situation and Goal
Hewlett-Packard's Medical Products Group, headquartered in Andover, Massachusetts, is
a leading provider of clinical measurement and information solutions, and services and support
for the healthcare industry. The group had 5,300 employees worldwide and revenues of $1.4
billion in its 1996 fiscal year. The Patient Monitoring Division (PMD) provides a variety of
products that acquire and process patient data in acute care settings, generally in hospitals. All of
PMD's products were traditionally made with custom hardware and embedded software, all
manufactured in house, that is, by HP. This is no longer the case; many are now being built
primarily from industry standard hardware components.
Patient data management products are a subset of PMD' s product line. They are one
step removed from the patient; these products manage, store, display, and analyze patient data
acquired from other monitoring products. For patient data management products in particular,
HP has made a strategic decision to use industry standard hardware components whenever
possible. PMD intuitively recognizes the value in leveraging the strides constantly being made in
computing hardware. HP's medical information management tools are largely computational, so
HP can enjoy much faster increases in capability with minimal product redesign by using
industry standard computation and data handling hardware.
Like many other companies and HP divisions, PMD has been evaluating its supply
chains, considering where it might increase or decrease the level of outsourcing. PMD has
already taken a step away from vertical integration in its use of industry standard hardware as a
base for many of its systems. From here, PMD must decide at what other points in the delivery
process to outsource processes, as well as how to transition from its current processes to the new
structure.
HP's decisions in these matters must be based on where real value can be added in the
supply chain. In the future customers will value product modularity and flexibility more than
they do today, due to increased technical sophistication and familiarity with the components of
patient data management systems. The structure of these products will be driven toward
modularity (that is, an ability to purchase only portions of the product functionality or
componentry) by market forces that were set in motion by HP's decision to use industry standard
hardware in them. Going forward PMD must select the pieces of a modular-product supply chain
that will best support ongoing strategic advantage for HP and will provide the best sales margins.
The goal of this thesis is to recommend supply chain improvements, recognizing future
market trends and where future value will exist. It will be contended that value (and therefore
lucrative margins) will be created in software design, as well as in process design for medical
software implementation; hardware handling will not carry value once current technical barriers
are overcome. This understanding should guide HP's sourcing decisions. The thesis will go on
to recommend and justify specific sourcing changes for PMD.
2 How this Thesis is Organized
This paper is designed to lead the reader through a market-based argument and to an
understanding of what considerations should drive PMD's decisions in outsourcing for its patient
information management products, as well as how HP might implement those decisions.
Chapter 2 provides a background in the industry and in HP's particular situation with
patient data management tools. It also makes clear the limited scope of this analysis, though it is
hoped that this analysis will help HP in further analysis of other products and sourcing decisions.
Chapter 3 discusses the outsourcing (make/buy) decision itself for these products. It
provides some structure based on an understanding of PMD's particular situation, as well as
based on academic writings. By the end of the chapter the reader should be convinced that HP
ought over time to outsource its hardware and hardware-software integration, but retain control
over its software design and process design for integration, testing, and installation.
Chapter 4 discusses the tradeoffs HP faces in implementing its make/buy decisions,
whether to make the change sudden or gradual, and whether to transition all information
management products to an outsourced hardware model together or in smaller subsets.
Chapter 5 presents recommendations to HP based on the analysis. It suggests a course of
action and the cost/benefit priorities that such a course involves. It further discusses changes that
HP must make in its organization and culture in order to be successful in following the suggested
approach. It includes some advice to HP for its supplier selection process. Finally, it offers a
suggested timeline for implementing the recommendations.
Chapter Two : Background
This chapter discusses the industry environment in which PMD operates, outlines the
scope of this thesis, and describes some issues that affect PMD's sourcing decisions.
1 Patient Monitoring
Industry Structure
The patient monitoring industry has traditionally been relatively slow moving and
conservative. This is primarily because of its customers. Hospitals and clinics, doctors, and
administrators are generally conservative, unwilling to risk patient lives on unproven
technologies. Also, patient monitoring systems are major capital investments and may remain in
use for many years. These two particulars of the industry combine to make product life cycles
long, on the order of 8-10 years. This is despite the fact that the technology level in the systems
is high, which tends to make product life cycles short; specific components within PMD's
products may themselves have life cycles of less than 6 months.
The industry is fairly tightly regulated by the Food and Drug Administration (FDA) in
the United States and other agencies worldwide. The FDA has defined good manufacturing
practices (GMP) for methods, facilities, and controls used for the manufacture, packing, storage,
and installation of medical devices. Manufacturers must prove to the FDA and other agencies
that their processes are well defined, and that their devices are being manufactured strictly
according to those processes every time. However, the specifics of GMP are not entirely clear in
this world of industry-standard computing hardware and custom software. Opinions differ within
HP regarding how much control is required over the software image, installation activities, and
the variety in the hardware used. For the purposes of this thesis, we will assume that it is
possible to design and define processes to a sufficient level of detail that they can be performed
by a non-HP partner.
Most revenue comes from large orders, usually from hospitals and clinics that are either
expanding or renovating facilities. Some other large orders are for replacement of older
monitoring systems. Because these large orders are usually part of capital planning, a short
delivery lead-time is not critical. However, the configuration details and desired delivery date
may change quite a bit right up until shipment. Furthermore, customers consider it extremely
important that everything be delivered on the promised delivery date. Customers don't want late
delivery of their monitoring technology to hold up the opening (or re-opening) of a hospital wing,
for example.
There is a distinction between independent hospitals and larger companies that may own
many clinics and hospitals. The primary difference between these operators for purposes of this
thesis is in their levels of technical expertise. Some large companies have information
technology departments that manage every aspect of hardware and software within their
facilities. They likely have negotiated company-wide contracts with hardware and software
providers, and they may perform all of their own integration and installation activities. They
generally have significant bargaining power versus HP, and can demand the kinds of products
they want. Independents and smaller companies may not have a very sophisticated information
technology function. They are more likely to need (and be willing to pay for) HP's full-service
approach to medical systems delivery. According to the American Hospital Association,
hospitals are roughly equally split between independents and larger management bodies, which
suggests that both kinds of customers described above will continue to exist for some time.
The shift toward modularity in patient data management products is and will be at least
in part due to increased sophistication of larger institutions. For example, it is now possible to
purchase only selected analysis algorithms in a data management product, where previously all
algorithms might have been bundled into the system for efficiency in design and integration.
Customers are becoming less willing to pay for what they do not need or want. As it becomes
more technologically feasible for monitoring providers to modularize their products, they are
working to provide an "a la carte" product solution, whether implemented in separate products or
in a single product, configured to customer specifications. Effort spent on modularization is
clearly not spent improving the products in other ways; to some extent this market change is
holding up product advances. However, the drive toward modularity is coupled with the
increased leverage of industry standard hardware, so patient data management products as a
whole are probably improving faster now than they were ten years ago.
HP's Position
"More than 80 companies produce patient monitoring products, but they all trail the
Hewlett-Packard Medical Products Group" - Health Industry Today (May, 1997)
HP has been on top of the medical monitoring market for some time, and is generally
seen as an innovator in products and services. Because PMD is by far the largest manufacturer
of patient monitoring equipment, it has had the ability to offer a wider range of products and
services on its own. However, HP has also made strategic alliances with medical analysis
software vendors as well as other equipment vendors to broaden its offering. Customers see HP
as a single source for the largest range of patient monitoring tools and systems.
HP also leads the industry in redefining the products that customers need and that it
provides. It is a founding member of the Andover Working Group, a consortium of over 200
application and equipment vendors, healthcare providers, systems integrators and consultants.
The Group's goal is to develop standards for and deliver inter-operable, object-oriented software
for healthcare applications.
Manufacturing Strategy
At a high level, PMD's manufacturing strategy has been designed to provide quality
products, ensure GMP, and manage inventories effectively. PMD has only three manufacturing
sites for its devices worldwide. It maintains multiple manufacturing sites for its more important
products, but focuses each of its sites as a center of excellence for particular product types.
HP overall is a leader in supply chain management, particularly in the technique of
postponement, or manufacturing generic products as far along the supply chain as possible, only
customizing them for particular customer needs once customer demand and product mix have
been firmly established. PMD works to incorporate postponement into its manufacturing
strategy primarily through configuration - the same software can be used for multiple systems,
and the customer-specific configuration is created during software integration, very shortly
before the products are shipped.
2 Scope of Analysis
The scope of this thesis is broad in terms of subject, but it only entails a portion of
PMD's product line. The content of the analysis is oriented toward supply chain structuring, and
how HP might source its products over the next several years. It centers on manufacturing, but
the arguments of Chapter 3 depend on movements in customer markets, and much of the
implementation depends on high level organizational changes and a refocusing of Research and
Development activities. However, the technical concerns that HP must address to implement the
recommendations that follow are beyond the scope of this thesis.
A supply chain is the network of people, processes (designed processes in practice), and
material involved in taking raw materials and providing a product to a customer. It is most
commonly described as a series of processes, with people and material implied. The supply
chain in scope of this thesis is specific to only certain of PMD's products.
There are three major product functions in the patient monitoring business, listed here in
order of increasing scope (this thesis focuses on the second one):
* Sensors and Monitors - These products acquire data from patients directly. A variety of
sensors can register such patient information as pulse and respiration rates, temperature,
blood pressure, gas measurements, and oxygen saturation in the bloodstream, and provide
that information to bedside monitors. These devices are attached to and often travel with
patients. They often have displays or hardcopy recorders attached to them, but they lack
network capabilities beyond the ability to send data over a proprietary network to patient
information management tools.
* Information Management Tools - These products deal with data provided from
monitors. They manipulate, store, analyze, move, and display the data. They often form
the interface between proprietary monitoring networks and industry standard hospital
information networks.
* Clinical Information Systems - These systems manage patient data at a higher level,
although they often interface with patient data management tools. CIS are designed to
manage all relevant data for the patient's stay in a facility, including billing information,
treatments, physician data, and an appropriate subset of monitor data. These systems are
generally modular, with software able to run on multiple hardware platforms and able to
interface to a variety of other products.
Figure 2.1 illustrates this categorization of patient monitoring products.
Figure 2.1: Categorization of Patient Monitoring Products
This thesis is only concerned with patient information management tools, situated
between monitors and clinical information systems. This is because the author's experience
within PMD has been focused on data management tools, but also because these products will
provide the richest ground for discussion of where value is truly added, and what HP should do
to maximize long-term strategic advantage. For sensors it is agreed within PMD that
manufacturing them is a core process competence; for these products HP will definitely remain
more or less vertically integrated. In certain business areas within PMD, such as CIS, the
software applications are the key value added. The implication of this is that software can be
sold separately from hardware, which increases the flexibility and management challenge in the
supply chain.
Throughout this thesis, generalizations about PMD's products should be understood to
be directed only toward patient information management products, unless otherwise specified.
Applications to other parts of PMD's product line, while they may prove valuable, are outside
the scope of this thesis.
3 Patient Data Management Products
Patient data management tools allow for the analysis of patient monitor signals both by
software algorithms and by people. For example, using a central station a nurse might identify
something unusual about a patient's heart rhythm (or the tool might identify it to him) and ask a
cardiologist to access and review the "event" data from a client data display in her office.
The most common of information management tools is the central station, which receives
data from several bedsides within a ward, and displays it to the doctors and nurses managing the
ward. Although they are a subset of patient data management products, central stations show the
technical attributes relevant to this thesis. Central stations manage many activities at once, in
real time. They may do any or all of the following:
* Receive patient data signals over a proprietary network from one or more bedside monitors
* Analyze the signals for abnormal conditions, sounding alarms if patient data exceeds
established conditions for concern
* Display the patient statistics to nurses, doctors, and monitor technicians using a graphical
user interface
* Route data to a recorder, which prints a hardcopy report
* Route data to other patient data management products, such as client data displays (remote
systems for data display only) or monitor tech workplaces (systems that allow technicians
to monitor many patients at once).
* Store a local version of the data (to maintain a copy if the network goes down)
* Send the data to an archiving server
* Interface to patient care recording systems to log events relevant to the care record.
A central station might consist of a high-end, dual processor PC with enhanced video and
sound cards installed, a proprietary network card installed, and the speaker volume control
removed. It could be running Windows NT and HP's proprietary software, which has several
HP- and third-party-developed software algorithms designed to analyze waveforms (data signals)
from bedside monitors. It would likely have with it a large monitor (or two), a recorder/printer, a
trackball for easy control, and an uninterruptible power supply (UPS). The older, integrated
systems would have been a single processor/monitor unit, built from fully custom hardware
components with a single-purpose application/operating system, but with similar external
accessories.
The supply chain for patient data management products is illustrated in figure 2.2.
Figure 2.2: Supply Chain for Patient Monitonng Products
The three links "Customize Hardware", "Integrate Software", and "Configure & Test"
are sometimes referred to together and more simply as "Integration & Test". Customizing
hardware consists of the installation of proprietary hardware extensions, such as the proprietary
network card, as well as some modification of the hardware itself, such as the removal of a PC's
speaker volume control. Integration of software involves loading of the operating system,
specialized hardware drivers, and the application software in a generic form. Configuration
involves customizing the software for the customer's application, enabling the options that the
customer has purchased, and testing the configured system to ensure that it is functioning
properly.
The links are all interdependent, more than simply with respect to sequence. They
depend on each other technically as well. For example, as shown in the next section, sourcing
hardware can be very difficult if the proprietary hardware and software are particularly sensitive
to variation in the standard hardware. Also, design of the software can significantly affect the
amount of technical expertise required to integrate, configure, and test the software. Before the
management of this supply chain can be outsourced, the integration and test processes must be
made both more robust to hardware variation and more simple and self-contained; this is
primarily an issue of software design improvement.
4 Current Challenges and Issues
HP's information management tools are not easy to build with industry standard
hardware. Software performance is critical, and it must perform in real time every time.
Although bedside monitors are designed to set off alarms if a patient's signals move outside
acceptable parameters, it is often the information management tools in the hallway that are being
actively watched by medical professionals. In some cases (such as telemetry monitors that allow
patients to move about the hospital with only a small transmitter) there is no bedside at all, and
information management tools are the only source of alarm should something go wrong with the
patient. Healthcare providers (and HP's reputation) cannot afford to have technical problems
arise in acute care. HP's traditional strengths in hardware development and manufacturer no
longer help as much when the hardware is outsourced.
Patient data management tools are intense, real-time, specialized applications. As
currently designed, they consistently use considerably more of a processor's capacity than is used
by more demanding office users. As faster chips and data buses are developed, this will become
less of an issue, but currently it makes products extremely performance-sensitive.
Hardware component performance is often not guaranteed to the strict tolerances
required by PMD at the upper levels of the performance spectrum. The cost-management
approaches of major hardware manufacturers are good for consumer and business applications,
but it puts performance at risk for PMD's applications. PMD has been forced to take a "try it
and see" approach to the hardware it uses. One lot of hardware components may work with the
current software, but the next may not. This is commonly because of changes to lower-level
components within the hardware. The changes are considered minor enough that for most
purposes the hardware is identical, but they may cause unacceptable software performance
problems for HP.
For example, in one industry standard computer used by PMD, a vendor began shipping
machines with new hard drives that have more capacity and a faster data transfer rate. The
vendor considers this an enhancement, and most customers would appreciate such an
enhancement. However, with the increased data capacity, the initial time required to access new
data blocks increased. This increase created unacceptable delays in some software functions,
requiring that PMD modify its software to accommodate the "improved" hardware. PMD must
either control its sources or develop its products such that they are robust to the variations that
naturally occur in industry standard hardware.
PMD is a small user of computing hardware, compared to the major suppliers in the
industry standard hardware market. As such, PMD has limited leverage with its suppliers to
control the hardware that is shipped to it. At the very top end of the hardware performance
spectrum the market is much smaller, and PMD has relatively more leverage; however PMD's
volume never exceeds 10% of its primary hardware supplier's total. When problems arise,
suppliers are often willing to help, but they will not freeze hardware configurations for PMD's
benefit at the volumes PMD requires.
HP's current work-around for this situation has been coined "homogeneous lot
verification". For certain products and components, it negotiates with vendors that they will
provide homogeneous lots - that is, that all lower-level components will be the same for all items
in each lot. PMD then orders hardware in month-sized lots with several weeks of lead-time.
Engineers verify the homogeneity of the lot, test the hardware in great detail, and ensure that the
software will work properly with it. Once the tests are complete, PMD can use the entire
homogeneous lot and expect no configuration problems. If there are problems with a lot, PMD
uses the long lead-time remaining to make changes to its software or get the problems fixed by
the vendor. This way PMD can keep shipping with good hardware while it resolves any issues.
Homogeneous lot verification creates a number of sub-optimal results:
* Demand must be planned months in advance, and investments in component hardware are
locked in long before customer demand is clear.
* Inventory investment is substantial. Hardware is a substantial part of the cost of PMD's
finished systems, and maintaining weeks of safety stock inventory creates large carrying
costs. Although PMD enjoys the forecasting insurance provided by the long lead-time,
the cost is not warranted.
* Due to the special accommodations asked of component vendors, and the large lots
required for efficient testing, it is difficult to maintain multiple sources for components.
Supplier shortages are a particular concern at the high end (top 10% in performance) of
the industry standard hardware market.
The costs resulting from these challenges outweigh many savings that might be gained
through novel sourcing of PMD's products. Moreover, it will be impossible to undertake more
radical supply chain changes without resolving these issues, as it would be unreasonable to ask
(or pay) for an outsourcing partner to take on the processes and inventory associated with lot
verification.
This chapter has described the PMD's environment and product line. It has outlined the
supply chain for patient data management products, and described some of the technical
challenges currently facing HP with these products. These challenges have made long-term
strategic analysis of HP's supply chain difficult. However, the strategic direction HP should take
relies on solutions to these issues. The remainder of this thesis will show how practical steps
that PMD can take over the next few years will help it resolve technical issues by adding to its
learning while creating internal pressure for HP's engineering talent to address those issues. The
next chapter will describe strategic drivers of the outsourcing decision, and relate them to these
technical issues.
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Chapter Three : The Decision to Outsource
Outsourcing is often considered as primarily a cost-cutting measure. This chapter will
present a case that relies on strategic considerations rather than on any particular costing
analysis. Making decisions based on cost alone is risky because it ignores the primary reasons
people buy HP systems - functionality, service, and reliability. However, the justification in this
chapter arises out of a supply chain costing model developed by the author for Hewlett-Packard
in 1997; the model is summarized in Appendix 1. The chapter will first suggest that HP will
eventually be forced to offer modular software products that customers integrate themselves. It
will then argue that in the future design of software as well as integration processes will be the
main drivers of value. Finally, it will suggest that HP can outsource products as a step toward
developing the right competencies in the world of unbundled products.
1 Bundled and Unbundled Software
Right now most medical monitoring software is sold as a bundled package with
hardware, software, and some services included, for a single price. Most tax-processing software
(for example) is sold unbundled, and the user purchases it expecting to provide his own hardware
and to install it himself. Unbundled solutions may be sold "off-the-shelf" or customized, but by
definition they are sold "a la carte".
For PMD today, bundling means that it provides monitoring software fully integrated
into hardware, fully customized and configured to customer specifications. Another division
provides installation services (bundled into the sales price), completing a turnkey solution for
HP's customers. In addition to the fact that medical information solutions have generally been
sold bundled, bundling has some advantages:
* It enables complete control of the product and the implementation of the design, in
accordance with Good Manufacturing Practices.
* Customers often prefer a turnkey solution, with a single quote, order, delivery, and
invoice, and installation team.
* Many customers would not be able to integrate and implement software solutions on their
own.
* HP is known in the market as a great single-source vendor; providing turnkey solutions is
a core competitive advantage for PMD.
HP will probably provide turnkey solutions to at least some of its customers for a long time to
come. Note that turnkey systems can be built from unbundled, modular components, so that HP
can continue to provide turnkey systems whether or not it builds modular products and offers
them to other customers unbundled.
However, the unbundling of medical software solutions is inevitable. Market forces will
eventually force PMD to offer unbundled software solutions. Customers will be able to purchase
software only, or combinations of software and hardware and services as they see fit. A number
of forces will contribute to the change:
* Large, savvy customers know that they can source and install standard hardware more
cheaply than can HP's field organization.
* Once customers can easily identify the hardware components and price them out
themselves, the value perceived in the bundle may be reduced below HP's delivered cost,
so the software will need to be priced separately. Some customers will demand that they
be allowed to integrate and install software themselves, on their own hardware.
* PMD should expect its competitors to push the market in this direction by offering
unbundled products themselves. To the extent that providing a turnkey solution is HP's
competitive advantage, competitors can diminish that advantage by shifting customer
expectations toward unbundled products, provided that their prices and quality are at least
as good as HP's. Competitors may be able to increase perceived value by offering exactly
the components that customers want at better prices.
As mentioned earlier, HP in fact started the trend toward unbundled software by leading
the patient monitoring industry in the use of standard hardware. By building systems on
industry-standard hardware, HP was increasing its advantage by leveraging technological
advances and cutting costs; but it was also modularizing the product, shifting the product's value
away from the particular hardware provided toward the software itself. Once the industry
follows HP's lead, customers will value the system purely by the software, and will in many
cases be unwilling to pay PMD for anything but the software.
"An innovation that raises a firm's competitive advantage may eventually undermine
industry structure, if and when the innovation is imitated." -- Michael Porter (1985)
Changing Industry Structure - The Double Helix Model
PMD has lived in a vertically structured industry for the past three decades, but the
industry is becoming more horizontal, i.e. the products are becoming less integral and there are
more stages (and competitors) in the supply chain. This changing structure is not random, but
rather the result of a tension between forces driving toward verticality and others driving towards
a horizontal structure.
Fine and Whitney describe this tension with what they call the "Double Helix Model."
(Fine & Whitney, 1996; Fine, 1998) They provide, as one example, the computer industry over
the last few decades.
From the late 1960's through the early 1980's, the computer industry was vertical. There
were a number of players, but they were all vertically integrated. They provided all the key
elements of their own computer systems, from the operating system and applications software to
the base hardware, rather than supplying modules and bundles provided to them by third parties.
The products and systems all exhibited integral architectures, with little or no interchangeability
between parts from different suppliers. Each company provided all elements of the final system,
and so had to maintain all of the capabilities required to provide each of those elements. IBM
was the dominant player in this industry.
In the late 1970's, the Apple personal computer appeared. IBM chose to launch a
competing product, and its PC division chose to break from the vertically structured tradition.
They designed the IBM PC modularly, sourcing processors from Intel and the operating system
from Microsoft. This decision was made for the sake of speed and cost, but it precipitated a
major change in the industry. The PC industry quickly became horizontal, with different players
staking out their claims on pieces of the supply chain, and with different players becoming
dominant in different pieces of the architecture.
This same shift toward horizontal structure appears to be happening in cars and in
aircraft. While some people might claim based on the PC story that all industries are driven
toward horizontality, Fine and Whitney claim that the horizontal structure is no more stable than
the vertical one. For example, even in the PC industry, there are suggestions that horizonal
powerhouses Intel (processors) and Microsoft (operating system) are using their strength in their
section of the supply chain to expand their sales vertically. Intel is building PC motherboards
and incorporating video and sound processing into its products. Microsoft is increasing its sales
of applications and network management software, is integrating Internet software into its
operating system, and is providing multimedia content and delivery through that software.
The general form of the double helix model is illustrated in figure 3.1.
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Figure 3.1: The Double Helix model (adapted from Fine and Whitney, 1996; Fine, 1998)
Whenever an industry is integral, it feels pressure to dis-integrate from three forces:
* The attempts of niche competitors to enter and take over pieces of the system that can
reasonably be segmented out of the integral products
* The difficulty felt by market leaders in staying ahead on all of the many dimensions that
create advantage in the product (for example, software and hardware and networks and
operating systems)
* The organizational inertia that tends to settle on large, powerful companies.
All three of these contributed to the demise of IBM's vertical hold on the computer industry.
However, when (or once) an industry becomes horizontal or modular, there are pressures
that drive it back toward a vertical structure with an integral product. Again, three forces drive
the industry away from stability in a horizontal form:
* Each portion of the architecture can develop very stiff competition. Over time, winners
can emerge and take over the majority of the market for a particular component. Those
winners have a significant amount of market power, and they may try to parlay that power
into more sales. The logical expansion of sales through market power is into the
neighboring segments vertically. This is what may be happening with Intel and
Microsoft.
* Significant technical advances that do not fit into the dominant modular architecture may
require an integral product architecture to be used at all.
* Proprietary systems are very attractive due to their profitability.
How does the Double Helix apply to HP's Patient Monitoring Division? The medical
monitoring industry has been vertical for quite some time. However, HP began a transition by
building systems on purchased hardware, just as IBM began a transition by selling its PC with
purchased processors and operating systems. HP began using industry standard hardware to help
manage the complexity of new systems. By purchasing hardware and operating systems, PMD
could focus on developing monitoring solutions that integrate the best-of-class patient data
analysis tools (some purchased from other vendors) and manage large amounts of patient data in
a user-friendly way, while integrating smoothly into hospitals' data architectures. However, the
double helix implies that the industry as a whole, not simply HP's products, will become more
modular.
If HP does not adapt to the new emergent reality in the industry, HP will risk losing its
leading position in the patient monitoring industry. IBM lost its leadership in PCs by remaining
slow and dedicated to a vanishing world. PMD must prepare for a horizontal structure in the
patient monitoring industry, with unbundled hardware, software, and services, or risk IBM's fate.
Fine (1998) goes on from the double helix to extend the definition of the supply chain to
be the "capability chain". The capability chain focuses not on individual products or processes,
which are all too transitory, but rather on the functions of the chain, such as "provide patient data
to nurses and doctors in real time." He suggests that in industries that are becoming modular, the
winners are those that control the dominant capabilities, either products or processes that can
provide necessary functions that few others can perform; these are the capabilities that promise
higher margins. For example, winners in the PC industry include Intel (controlling
microprocessor design and manufacture) and Dell (uniquely capable of managing suppliers to
provide quick turn-around with very low inventories.) The remainder of this chapter will argue
that the dominant capabilities in the patient monitoring industry of the future will be robust
software development and integration process development, once the hardware and integration
execution become commodities.
Practically stated, PMD will eventually find itself in a modular industry, and it should be
prepared to control the most important capabilities within it. But remaining a purely vertical
provider of an integrated product is not a viable option, even according to market-watchers
within HP. Estimates within PMD vary as to exactly when customers will demand the ability to
buy software only, but in interviews with HP marketing and development personnel the author
did not get any estimates beyond 5 years. It is clear, however, that PMD will have to offer both
bundled turnkey solutions and unbundled software in the future. This means that the customer
will be loading and testing HP's software himself. And PMD risks being overtaken by a
competitor (albeit only if the competitor has solid quality and functionality at a reasonable cost)
if PMD takes too long to prepare itself to offer unbundled software.
Implications of Unbundling
The eventual unbundling of software from hardware will necessitate some changes
within PMD. Because HP will not be part of the integration and installation processes in all
cases, PMD must develop simplified processes and procedures for building the products, so that
HP's specialized expertise is no longer required.
More importantly, HP must be sure that the final product works and performs adequately
to ensure patient safety. In an unbundled environment, HP has less direct control over the
integration of its products, so liability risk increases if processes are not performed properly. It
will require a way to control that liability - carefully written contracts, tests for product quality
that are "idiot-proof', easily executed and unambiguous as to whether or not they were passed
successfully, and methods of proving that customers did or did not run the tests and observe their
results properly.
2 Product vs. Process Competence
This section makes a distinction between product and process competence. Both are
important, but each has unique implications for the supply chain structure. PMD must maintain
some process and some product competencies for its patient information management tools, but
only those that add unique value; others may be considered for outsourcing.
Product Competence
Product competence is in the design of the product itself, rather than in how it is made.
One example of product competence is Coca-Cola. Although the process by which Coke's
concentrate is made is kept secret, the "specialness" of the product is in the recipe, the design of
the product. Many new high-tech products exhibit product competence only, because new
companies often have a great new technical design but must outsource production or at best
cobble it together in-house.
Most shrink-wrapped software's unique advantages are in the product itself - because
software is almost all design and almost no manufacture, software manufacturing processes
usually have little to do with the value perceived in the end product by customers.
This is not to say that product competence does not involve a process. Many of HP's
consumer products exhibit product competence, yet they do so because of internal processes that
appropriately structure the product and supply chain. HP maintains a lead position in printers,
for example, due not to manufacturing processes as much as to its ability to consistently
introduce new, high-quality products before the market as a whole catches up to its current
offering. Intel takes a similar strategy a step further, by following a rigorous process for bringing
manufacturing up to high volumes quickly and with high yield.
For PMD, Product Competence = Hardware + Software Competence
The product competence in PMD's patient data management products is conceptually
separable into hardware and software competence. The hardware must be reliable and fast. It
must be able to handle the load placed on it by the software and users. The software must
perform an ever-increasing variety of functions without fail. It must not overload the hardware,
yet it must recognize when it has done so (or failed in another way) to avoid putting patients at
risk.
By transitioning to industry standard hardware, PMD is eliminating the value in
hardware competence. PMD's information management products require quality, but they are
sold based on functionality. New data analysis algorithms and new features for users are the
primary sales drivers of these products. That is why the software is the primary product
competence while the hardware is becoming a commodity. This was not the case a couple of
product generations back, but PMD made the decision that designing hardware was not the most
efficient way to get functionality to the market. PC manufacturers are already designing and
building high-performance hardware, so PMD is leveraging that investment by outsourcing or
purchasing most of the design and assembly of its hardware.
However, right now hardware design control is a major activity within PMD for some
hardware components. PMD performs homogeneous lot verification for some components in a
kind of ex-post control; for other components it negotiates design freezes for its version of a
standard component. In these cases PMD is really outsourcing the manufacture of special
components rather than buying off-the-shelf. This is because even though these components are
standard product configurations, PMD imposes special design and process controls on its
vendors. This kind of outsourcing is not intrinsically bad, but to a degree it locks PMD into
staying with those suppliers in which it has made the design and process control investments.
This makes flexible sourcing more difficult for PMD.
As long as the software is not separable from the hardware due to technical
considerations, HP is investing in hardware control that adds no value from the customer's point
of view. The homogeneous lot verification process is simply a check that components will
perform adequately with HP's current product and process design. Value is only provided
through the absence of a technical problem. That value is perceivable right now, because HP's
competitors have the same technical problems. However, if one of HP's competitors resolves the
issue, it could eliminate the cost of providing that value while HP would still be forced to pay to
provide it.
Apart from technical (process) difficulties in implementing the product design, the
software is the remaining product competence. It is where the functionality resides, and
therefore where customer value is added. That said, increases in functionality will require
increases in hardware performance. If the increase in technical requirements can be made slower
than the industry-wide increase in hardware functionality, then the technical difficulties should
decrease over time. Opinions are divided within PMD, and even within its R&D function, as to
whether its products will require top-end hardware for the foreseeable future, but it is clear that
PMD's engineers will gain experience with such hardware products that help improve its
management of the technical issues.
Process competence
Process competence lies in a provider's execution capabilities, and the design of its
demand fulfillment processes. For example, Dell's designs have little to do with its success.
Rather Dell's unique processes to manage vendors and inventories, to customize customer
interactions, and to deliver products with surprising speed, provide Dell with its special position
in the PC market.
Most great companies succeed through a combination of product and process
competence; they know what to make and what processes are the most important in providing it
to customers. Coca-Cola shows process competence in addition to the product competence
mentioned earlier. Its ability to manage its brand, and to ensure that a Coke is always available
when impulse strikes a customer, are powerful contributors to Coke's success. It further
recognized that syrup production was the most profitable capability in providing its drink to
customers, so it divested bottlers and focused primarily on that. While people differ on the
extent of Coke's product competence, these process competencies are undeniable. Intel's
process competencies include its ability to design new processors very quickly, to execute
technical specifications that few others can match, and to ramp up chip manufacture faster than
anyone else in the industry. These delivery process competencies, combined with Intel's brand
management process competence, enable Intel to lead or even control its industry.
HP's process competence in patient data management tools lies in manufacturing, test,
delivery, and installation processes. However, HP's unique (non-outsourcable) process skills lie
in the development of these processes and in customer management. This is partially because
these skills have been required of HP Medical for longer than any product or technology's life-
cycle, but partially because they provide the greatest value in the capability chain.
As a leader in the medical products industry, HP Medical must have process development
and control as a core competence. PMD's relationship with the FDA relies on that. And if we
remove process control and customer order management processes from the picture, the
remainder of the integration processes are non-core; they are also becoming commodity
processes. This is not apparent today, however. There are two reasons why PMD's current
hardware and software integration processes appear (misleadingly) to have core competency
elements:
* The software is not always robust enough to work on commodity hardware. Right now in
order for PMD to offer some products at all, PMD must do the integration and test the
hardware, to ensure that the product will work reliably. If the software design becomes
somewhat more robust to variations in hardware components, and PMD develops
software tests that are performable by other partners, then hardware integration and
testing will clearly be commodity.
* Within the integration and test processes, process control cannot currently be separated
from the process itself. The processes are not yet stable enough and simple enough for
them to be viewed as decomposable into the management of the process and the execution
of the process. Because process management must remain a PMD competence, the
process execution must remain within the organization until it can be separated from
customer and process management.
Because of the delivery processes currently performed by HP will in the future be
performed by customers or by third-party providers, either within or outside HP Medical, PMD
does not have complete control over the execution of the processes it designs. Therefore, they
must be more robust in order to provide similar value. This implies an increase in cost for the
same product, but it is not a cost that customers will want to pay. Instead, HP must depend on its
ability to design robust implementation processes whose increase in cost is less than the
perceived increased value customers see in the unbundled software product. This perceived
value increase is likely to be small, particularly if multiple competitors are offering unbundled
software products; thus low-cost HP process development capability is crucial to its leadership
position in the patient data management market.
3 Competitive Advantage in the Unbundled Product Market
The primary new feature of the unbundled product market for HP is the fact that with an
unbundled product, PMD will not be executing many of the delivery processes. They will
instead be performed by customers or by third-party providers. HP is entering a new market
type; or, rather, is changing its own market to a new type. It will be providing software
independent of hardware. Independent software is a difficult market in which to make money.
HP must maximize the value it provides to customers, through its structuring of the capability
chain, or a competitor may try to steal its position.
Selection of Core Competencies
Common wisdom today says that companies should retain competencies that are integral
to their value proposition, while where possible outsourcing the others. Quinn & Hilmer (1994)
describe four ways in which this approach maximizes firms' return on resource investment:
* It concentrates investments and energy on what the enterprise does best, while avoiding
investments in areas that do not provide such high returns.
* By leading the industry in certain capabilities, it builds barriers against competitors that
(now and in the future) try to expand into the enterprise's market space.
* It fully utilizes external suppliers' investments, innovations, and special capabilities, that
would be expensive or even impossible to duplicate internally.
* It decreases risk, increases speed, reduces fixed investment, and allows better
responsiveness to customer needs.
Although there are concerns to be weighed against these advantages, all of these advantages do
apply to PMD. HP has limited resources available for product development and management,
needs to control its fixed investment and respond to customer needs, is working to protect its
market position by leveraging hardware developments and other supplier capabilities that it
chooses not to develop internally. Exhibit 1 describes the author's supply chain analysis that
showed it to be infeasible for PMD to develop many of the capabilities that it is already
purchasing, and showed that outsourcing further might have cost advantages.
Venkatesan (1992) further drives home the idea that management must consider the
value of focusing on only a few skills when deciding how to allocate attention, based on
interviews with hundreds of managers:
"Few managers seemed to appreciate the true opportunity costs of investment in such
intangible resources as management attention and engineering talent. They failed to
realize that their 'we can do it all' mentality was, in effect, depleting the limited energy
their people had for changing manufacturing routines, let alone strategic thinking."
The effort spent on managing whole sections of the capability chain in which the firm does not
excel is effort not spent enhancing those competencies in which the firm is a leader.
However, firms must consider the possibility of losing control of even their strengths if
they rely too much on outsourcing. The selection of the competencies to maintain can determine
the strength of the company relative to its suppliers.
Dependence on Capacity and Knowledge
Any time a manufacturer outsources, it risks becoming dependent on its supplier.
However, there is a significant distinction between dependence for product knowledge and
dependence merely for production capacity. Fine and Whitney (1996) expand on a concept they
credit to Geoffrey Parker, which makes this distinction clear. Dependence for capacity results
when a company could (and may currently) make the product in question in house, but for
reasons of time, money, space, or management attention chooses to use a supplier to extend its
capacity. Dependence for knowledge results from a case where a company lacks the skill or
knowledge to provide a necessary component, and therefore seeks an outside supplier.
It would be strange for a company to be dependent for knowledge while independent for
capacity. So the question raised is whether a company that outsources a process or component
becomes dependent on its supplier for knowledge and capacity, or merely for capacity alone.
The ramifications of dependence themselves depend on the architecture of the product being
outsourced. Modular architectures are divisible, so that dependence of either sort is contained
within a single component or process. Integral architectures raise the stakes substantially, so that
suppliers are more able to expand their influence into other aspects of the product. Figure 3.2
shows Fine and Whitney's concerns.
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Figure 3.2: The Matrix of Organizational Dependency and Product Decomposability (Fine/Whitney, 1996)
If we apply this concept to HP, we immediately see a concern with the outsourcing that
PMD has already undertaken. PMD has voluntarily become dependent for hardware capacity.
Furthermore, PMD is at least somewhat dependent for knowledge for their industry standard
hardware. While PMD's engineers understand hardware very well, they choose not to maintain a
deep skill-set in the computational heart of the hardware they buy; that is, they could not
themselves design the hardware they use. According to Fine & Whitney's general model, this is
a concern. If the product is integral, they would be in the worst outsourcing situation; if it is
modular, they still would be in a potential trap.
However, as PMD has decided to build products with industry-standard hardware, it has
also driven the hardware portion of the product toward modularity. It is working to make the
hardware entirely interchangeable within a limited set of product specifications. PMD is moving
out of the lower left quadrant up to the upper left as it reduces the dependence of its software on
its hardware.
Note that this points toward the necessity of further disintegration. Fine and Whitney's
general model has predicted the issues that PMD faces with the robustness of its software. The
clear imperative is for PMD to make the product truly modular to get out of the "worst possible
outsourcing situation". And although the general model says that the upper left quadrant is not
much better, in PMD's case it can be considered a safe haven. Safety comes through being a
small part of a big commodity market.
Fine (1998) adds the number of suppliers to dependence and modularity in the matrix.
His point is that dependence on an industry is less dangerous than dependence on a single
supplier. Hardware is becoming a commodity industry, with many players offering substantially
the same product. As long as the software works on many hardware products, PMD is less
susceptible to holdup because of its ability to change suppliers. This makes the robustness of
software to hardware variation a strategic sourcing issue, beyond its current cost implications.
The raw computing hardware market is very large. However, PMD and the entire
medical monitoring industry is using only a very small portion of that hardware. It would be very
surprising for an industry standard hardware manufacturer to try to move into the medical
market. The other competencies are simply too expensive to develop. So as long as PMD
creates a modular architecture for its products, and is merely outsourcing hardware manufacture,
it can consider itself safe despite its dependence for hardware knowledge. This does not,
however, reduce the competitive risks created by a modular product structure; it is just that the
risks are from medical monitoring competitors rather than hardware manufacturers.
Hardware manufacture, software development, integration, delivery, and customer
management are very different links in the capability chain. If HP becomes dependent for
knowledge on a critical piece of the capability chain, Fine and Whitney's model implies that it
can expect to lose its position in the market as the owner of the critical piece exercises its
newfound strength. PMD already outsources hardware manufacture and the risk is controlled. If
PMD maintains control over software development and customer management, it can control the
risks in outsourcing integration and delivery.
However, if HP outsources its software development indiscriminately, then it is
reasonable to expect that eventually the designer of the critical software components will go into
the medical information management business for himself. Fine gives some examples of where
this has happened in the past or is happening currently, such as PCs (IBM, Microsoft, and "Intel
Inside") and bicycles (Shimano taking the lead in the industry through controlling componentry).
Hardware Handling
Once we decide that software development is a core capability for PMD, we can examine
the physical supply chain for hardware. Figure 3.3 shows one way to look at the options PMD
faces for sourcing products.
Figure 3.3: Hardware and Integration Sourcing Continuum
PMD's hardware sourcing must fall in a range between producing everything in-house
and performing every process outside. As more processes are performed outside, PMD's work
becomes less production and more control. The software-only part of an unbundled product
solution is one step beyond fully outsourcing assembly, integration and test. It shifts process
execution out of PMD and beyond a third-party provider, all the way onto the customer himself.
HP currently maintains competence throughout its vertical supply chain, with the
exception of the base hardware manufacture. Some processes involve more special value than
others. In general terms, the value will increase as one moves to the right in the sourcing
continuum. This is due to two particulars of the product we are addressing:
* Functionality is primarily what contributes to customer perceptions of value.
Functionality is primarily defined by software, provided the hardware does not limit the
software's execution.
* The closer we get to the customer within a medical product supply chain, the more
important it is to control the quality of the product, and the more responsibility to the
customer (and the FDA) we take on. This value is provided in a negative way, in that it is
an absence of problems; as we move to the right in the sourcing continuum, it becomes
more imperative and more difficult to assure the absence of problems.
There is a tension within HP over the value in the absence of problems. Development and
manufacturing engineers clearly recognize the costs of ensuring an absence of product problems
to the customer. They also recognize that those costs will increase if we move to outsource
hardware handling, and probably increase further if we allow customers to integrate the product
themselves. However, marketing and PMD management appear to have faith that those same
engineers can control those costs; further, they believe that there will be significant value
provided by an unbundled solution. These two seemingly conflicting ideas within PMD are
resolved if outsourcing is considered to be more a step toward unbundling the product than it is a
short-term cost saving technique. If HP chooses to limit the capabilities that it maintains, the
easiest to shift outside are those to the left of the hardware and integration sourcing continuum.
And because eventually PMD must offer the unbundled solution to some customers, it should
minimize the costs in managing the hardware handling processes outside HP.
The Need to Focus
There are two major reasons why HP must focus on only the capabilities that add long-
term special value to HP's products:
* The significant change in the patient information management industry that PMD has
started will require as much managerial and strategic energy as possible be devoted to
maintaining a market-leader role.
* Eventually obsolete capabilities become liabilities, and deeply-ingrained competencies
can be difficult to change.
Leonard-Barton (1992) supports the positive aspects of focus on a limited set of important core
capabilities. However, she also cautions that core capabilities can become "rigidities" that limit
the enterprise's ability to adapt to a changing world. She describes these rigidities along four
dimensions, but the two that are most relevant to PMD's situation are the dimensions of technical
systems and management systems. If HP does not successfully retain the right competencies, it
runs the risk of establishing rigidities that make it vulnerable to new competition and market
changes.
If PMD retains all of its hardware sourcing capabilities in house, it will have a large
investment in technical skills on the hardware platform currently in use. There will be a number
of technical applications built for software load and integration that rely on the current
generation of components. As the best architecture for the product changes, HP may be reluctant
to scrap that investment to stay on the cutting edge.
PMD also has management structures, metrics, and processes established to manage a
hardware handling business. These systems will not serve PMD as well when it must ship
unbundled, software-only products. Customer-oriented metrics will clearly shift toward ease of
installation and use, and less toward delivered cost, for example. If PMD defines itself primarily
based on its hardware handling capabilities, it may find itself in a software world, without the
nimbleness it needs to address customer needs.
Implications for PMD
Because PMD needs to focus on only the most important capabilities for the future, and
because the smallest future value will lie in hardware handling, PMD should retain control over
the software product competence (including competence in maximizing robustness) and the
process development, while outsourcing hardware assembly and integration. This will allow
PMD to focus resources where value will be most concentrated.
However, it could reasonably be argued (although in interviews with personnel across
PMD it was never said outright) that PMD has a significant lead over its competitors in product
and process technology; perhaps PMD should leave the product and market intact while it is still
making strong margins on its products. After all, the market moves fairly slowly, and PMD
should have time to get to the next product paradigm before it is forced to. Why should PMD
hasten the demise of a profitable structure?
The response to this argument depends on one's view of the pace of change in medical
monitoring. If one believes that product life cycles will continue to be up to ten years, then the
only response is one of long-term strategy and an appeal to PMD's vision, which would suggest
that advancing the industry and the quality of patient monitoring in general is good independent
of short-term profits.
Many others believe, however, that the move to industry standard hardware will
("through osmosis" as one HP engineer put it) increase the pace of change in patient data
management products. In this environment, PMD will only stay on top of the industry by being
first to market with fully unbundled solutions.
Furthermore, HP should begin the process well before the market demands unbundled
solutions. The transition will take time, particularly if PMD follows a conservative transition
plan. Also, there is a strong synergy between readiness for outsourcing and readiness for
unbundling software and hardware.
HP must eliminate the dependence of its software on its hardware. It must eliminate the
requirement for homogeneous lot verification; hardware restrictions like that will frustrate and
worry customers. This will require substantial effort directed toward making the software
substantially more robust to hardware variation, and eliminating or fully controlling for the
barriers to real-time performance. HP must also develop implementation processes that can be
performed by any partner. In the extreme case of a software-only product, that partner will be a
customer, over whom HP will have very limited control.
Note that these technical requirements to offer unbundled solutions are the same as those
to outsource the hardware handling for a bundled solution. By moving to outsource hardware
handling, PMD can develop the competencies it needs for the future world that includes
software-only products. Outsourcing can be considered to include the first steps toward
unbundling the software products from their hardware.
Leonard-Barton provides a model for the development of core competencies. Projects
that leverage the core competencies of the enterprise are more likely to succeed; in turn, those
projects increase the strength of those competencies. This reinforcing cycle helps develop very
strong competencies, and increase focus. HP is in a position where it needs to grow its robust
software development and installation process development competencies.
By taking on a project to outsource hardware handling, PMD can exercise and develop
those important skills before it is forced to demonstrate them directly to customers. PMD can
jump-start the reinforcing loop of competency development. With the head start PMD develops
over its competition, it can leverage commodity hardware (for knowledge and capacity) and mass
integration services (for capacity only) to cut costs and increase the pressure on its competition.
Given that PMD will offer unbundled software to some of its customers, it must offer the
best perceived value per process to all of its customers. When customers ask PMD to perform
hardware sourcing and integration, it must be provided according to a particular value strategy.
For any particular level of functionality and service, it must be provided at minimum cost. By
focusing on robust software development and integration processes, while relying on outside
suppliers for hardware handling, PMD can maintain its market leadership and deliver at the
lowest cost possible.
Chapter Four : The Transition
Once PMD has made a decision to outsource its hardware handling processes, it opens
up a new set of questions. This chapter looks practically at the sub-strategies that HP should
consider when developing a transition plan. Multiple dimensions of the problem need to be
considered together.
1 Moving Products Together vs. Separately
A first consideration is how to group products for the transition to an outside production
process. PMD has a variety of information management software products, already at various
levels along the hardware outsourcing continuum. The products can be transitioned individually,
grouped by current level of outsourcing or by technology family, or all of PMD's patient data
management products can be transitioned at once.
The factors that point toward larger groupings of products are primarily organizational:
* A single implementation will probably take less time than a phased transition.
* The fewer separate transitions that must be managed, the less aggregate organizational
disruption is likely to occur. That is, the whole is smaller than the sum of the parts,
because each transition brings some disturbance which must be repeated for each
transition.
* Costs incurred in transition will be smaller, due to reductions in fixed (repeated)
transition costs, scale economies at the outsourcing partner, and reduction in interim
process management.
A 1997 supply chain cost analysis project conducted by the author showed that even if
process costs are reduced through outsourcing, costs will often increase if the process is
outsourced for too small a product group. This is because the support costs have a fixed
component, and are therefore non-linear with respect to volume. Small volumes must bear the
burden of all of the support costs, driving up unit costs. If PMD chooses to outsource products in
very small groups, then throughout the transition phases there will be many distinct processes to
support for different products, each expensive due to small unit volume.
The above notwithstanding, there are two primary reasons to suggest that PMD avoid
large groupings of products for the transition. The first is organizational - products are at
different stages of readiness for the transition. The second is risk, which is difficult for a medical
manufacturer to voluntarily take on.
Some of PMD' s patient data management products are very ready for outsourcing, while
others will require a significant amount of development effort before they can be successfully
transitioned to outside integration. This makes a single group transition more difficult. To change
the products together, PMD would have to pick an ending structure and move them all from
wherever they are to that point simultaneously. The timing of that transition will be much later
than is necessary for the products that are already very modular and partially outsourced.
Despite the increased support costs, PMD may be able to gain a significant head start if it moves
the easy products now.
Also, some products will entail risks to outsource, and managing those disparate risks
could make a single-group implementation take a very long time. There is a significant level of
risk associated with outsourcing medical device manufacturing. In particular, PMD is still
learning how to work with software products working on industry standard hardware
components. Some products are very sensitive to hardware variation and process controls.
Significant changes to the supply chain for these products will create risks that shipments will be
held up, or that product quality may suffer (which means that shipment will stop, because PMD
is unwilling to ship under-quality product). The financial risk is particularly great for products
that are often tied to large amounts of other PMD revenue. Moving lower-risk products first will
enable PMD to gain confidence and stabilize the destination supply chain before moving higher-
risk products.
A potential compromise might be to transition HP's products in two large groups,
maintaining as much scale economy as possible, while recognizing that some products will be
much easier to transition than others.
2 Pace of Transition
In addition to how to group products, PMD must consider the rate of change. Three
high-level alternatives will be identifiable as immediate, phased, and held.
Immediate
PMD could begin to establish the full outsourcing relationship immediately. This is a
form of "shock therapy". It is certainly going to produce the fastest results, but it also adds to the
risk of stopping shipment temporarily. If things go badly and yet shipments do not stop, then
there will be a risk of shipping bad products, which is unacceptable to PMD.
Because a large portion of HP's patient monitoring sales are tied to the ability to ship
patient data management products, the risk of stopping shipment for even a small group of
products carries a significant financial and customer service penalty. HP is probably not capable
of accepting this level of risk.
However, the risk of this approach is likely not as great as it appears at first glance.
PMD has skills in developing comprehensive contingency plans, and can show a lot of ingenuity
and energy when confronted with a problem. Provided the organization is committed to making
the relationship work, an immediate transition is not out of the question.
Phased
Here HP would identify the eventual partners for the full outsourcing relationship.
However, it would transfer processes to the partners only a little at a time, as the partners and
processes are ready. For example, PMD might ask the partners to inventory hardware and
perform initial hardware integration, but then ship the products to HP for software load, test, and
delivery to customers. In this case PMD might even maintain an extra inventory of integrated
hardware as a buffer to decrease supplier performance risk. Alternately, PMD might begin by
having contractors manage parts of the processes within HP, then transfer those functions to the
partner's facility after the processes are running smoothly between HP and the other organization.
This would enable PMD to iron out the information and order management issues before
any product or process issues arise. Risk is dramatically reduced. Another division of HP is
using this more conservative approach to outsource similarly integrated products. The
implementation is in its earlier stages, but all indications are that things are going smoothly.
The reduction in risk is purchased at a cost. The increased cost in this approach is
threefold:
* It takes longer to get to the eventual supply chain. Assuming that the eventual supply
chain is the most efficient, delays can be costly.
* During the transition, some of the process allocations between partners are much less
efficient. If outsourcing one process saves very little in process cost while greatly
increasing support cost, PMD will be producing at a higher cost than no outsourcing at
all.
* Support processes are established for interim steps which require rework or re-creation
for later steps. The multiple steps require much more process development, incurring
delays and costs.
If HP moves with a phased approach, it should expect costs to rise rather than fall during the
transition phases. Costs will be back in line when the transition is complete, but this could take
some time.
Held
PMD can take an even more risk-averse approach. It could implement nothing until
everything is ready, with the expectation that an immediate transition will be made when all of
the preparation is complete. By preparing the products and structures fully for the transition
before it is made, HP could minimize the risks in the transition.
The problem with this approach is that there will always be risks in a supply chain
transition such as this. The immediate transition can always experience problems, and even the
best engineers cannot plan for absolutely everything. Therefore, there will always be some level
of risk. Clearly preparation will reduce those risks, but the concept of waiting for a risk-free
transition encourages inertia. So there is a new risk with this approach that nothing will ever be
fully ready, and no change will ever occur.
Figure 4.1 illustrates the options, and how PMD might currently map onto them.
Figure 4.1: Transition Pace Options
3 Current Operating Paradigm
PMD is working to bring structure to a previously unstructured strategy. PMD's
management wants to do whatever is best for the products and the division overall. It wants a
unified high-level strategy, in that all products are considered together, whether the best decision
is to move them as a single group or in stages.
The emergent operational strategy at PMD has been to treat products separately, based
on very practical considerations. For example, some of HP' s patient data management products
are already very modular, and they are also very small in volume. These products are partially
outsourced now, and becoming more so over time. PMD has been making investments in
internal infrastructure for other products, planning to keep them in house due to their technical
complexities. The lack of coordination is not endemic; if PMD's management lays out a
coordinated, scheduled plan to handle all products, operations will be able to follow that course.
Along the pace dimension, HP is currently holding and preparing for most of the
products in the scope of this thesis. There is a limited of early stage phased work, but these
products are currently limited technically in how far they can transition. For example, if HP
cannot be sure that any hardware of a particular type will work properly with a software product,
it is extremely difficult to ask a partner to manage the hardware inventory.
Without a specific coordinated plan, practical considerations suggest that any individual
decision will be to hold implementation until outsourcing is less expensive and less risky. This
was in evidence in interviews and sourcing decision processes witnessed by the author during the
1997 supply chain cost modeling project. At the level of analysis for most sourcing decisions in
the absence of a division-wide plan, novel sourcing approaches suffer from three problems:
* Cost advantages will not be substantial, because all of the processes that are required for
the product under consideration in house would still remain in house for other products if
one product is outsourced.
* Without a history of learning or an organizational drive to try a new approach, the risk
perceived by decision makers will not be worth the perceived long-term advantages.
There can be general agreement that new sourcing approaches are required, but no
individual decision maker wants to take on the risk.
* PMD's customer focus creates a drive to bring new functionality to market as fast as
possible; making a change to the supply chain is (quite reasonably) perceived to increase
time-to-market for the first products to try it.
All of these concerns can be addressed in a unified PMD sourcing strategy. Leaders of
individual sourcing efforts will be more comfortable trying a new approach if they are able to
relate any cost, risk, or timing problems to the division-wide sourcing initiative. The personal
risk will be significantly reduced.
Moreover, if HP adopts a specific plan to outsource products, there will be internal
pressure to solve all of the technical problems that currently keep the organization holding. A
plan with a deadline may create the "burning platform" that HP needs to overcome inertia. Until
HP overcomes that inertia, it is leaving potential savings and strategic advantage on the table.
More importantly, a lack of direction relieves pressure on the development of unbundled
software solutions, which could leave PMD at a greater risk to competitors.
Chapter Five : Recommendation
The recommendation follows directly from earlier analysis - PMD must work to
outsource its hardware and software integration processes, while maintaining control of customer
relationships and software development. This chapter details a recommended approach to
outsourcing, making choices about the tradeoffs described in Chapter Four.
Because there is no single right answer to how HP should address sourcing for its patient
data management products, we must also consider the costs and benefits of the recommended
approach. The recommendations also include some practical considerations regarding changes
PMD needs to make as well as attributes of an ideal outsourcing partner. The chapter and thesis
will close with a potential task list and timeline for PMD to implement the recommendation.
1 Approach
To protect its current market advantage and position itself for future market leadership,
PMD should have a goal of outsourcing hardware integration, software load and test, and
delivery of its patient data management products. A clear schedule is required to coordinate
multiple efforts throughout the division, and top-down management support is essential.
Companies
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Figure 5.1 : Logical Structure of Analysis and Recommendation
Within the schedule, PMD should segregate its patient data management products into
two groups, and begin a phased transition to outsource the less technically restrictive group,
while simultaneously focusing technical development on reducing the reservations with the more
restrictive group. Once both initial efforts are largely complete, PMD can quickly phase the
second group of products outside.
Product Grouping
By segregating products, PMD can begin to gain experience in outsourcing without
incurring the risks that keep it from moving faster now. Call the groups "A" and "B", but
consider the two groups A = "easier-to-outsource", and B = "difficult-to-outsource".
Group A products are simply those that have no difficulties. Several things may lead
PMD to consider a product difficult:
* Manufacturing the system is an extremely intricate process, such that a partner might take
a long time to become competent, or good medical manufacturing practices may be hard
to verify.
* The system requires a large amount of manufacturing process control, such as
homogeneous lot verification.
* The system is typically at the heart of very large PMD customer orders, so that an
interruption in shipment would hold up a large amount of PMD revenue.
Group A products are likely already close to being unbundled, and are generally hardware-
independent. Group B products are considered too risky to move quickly. PMD can gain
outsourcing experience quickly while making it technically feasible to begin outsourcing its more
difficult products.
Phased Implementation
The implementation approach is broken into two major phases - move group A, then
move group B. However, while PMD is moving group A, it must also be advancing its
technology and processes to the point that group B is no longer so difficult. When group A is
moved and group B is outsourceable, PMD should move group B relatively quickly, to maximize
the organizational gains from outsourcing. Figure 5.2 illustrates the recommended transition
plan.
To move group A specifically, PMD will best be served by a phased implementation. To
maintain solid control over medical device manufacturing processes, PMD must phase the
transition, whether process by process or by maintaining capacity within PMD while establishing
the outsourced capacity. PMD's risk-averse nature would be at odds with any more aggressive
approach. During the phased implementation for group A, HP will be learning about the
processes and relationships necessary for successful outsourcing, and experiencing some of the
pitfalls along the way, in a lower-risk implementation.
Some group A products will include peripherals and add-ons to group B systems. To the
extent that these peripherals are modular and separate from the larger systems, they can be
outsourced very quickly. Hardware that does not require integration as part of the manufacturing
process can be merged with systems immediately prior to (or during) shipment to the customer.
Such hardware should be easy to transfer to a partner for management and can start the phased
implementation.
Concurrent with the transfer of group A products to outside production and inventory
management, PMD must be working to remove the technical barriers to outsourcing the
remaining (group B) products. Holding back on difficult products cannot be considered a
reprieve for the effort overall, or PMD will find itself with partial outsourcing that achieves little
cost benefit and very little of the strategic gains that it should be working toward.
If it takes two to three years to transition group A products to complete outside hardware
handling and software integration, it should take approximately as long to prepare group B
products to begin the same transition. The skill level of HP's development engineers is high
enough that if modularity is assigned a top priority, with a deadline built into the schedule, it is
very reasonable to assume that PMD's patient data management products could be fully modular
in two years, with no significant barriers to outsourcing all of these products.
Once the group B products are modular, and HP has accumulated learnings from
outsourcing the group A products, it should be able to implement an accelerated phased
transition for the group B products, taking perhaps half as long as the group A transition.
Although the group B products are important and risky, the implementation will have the
advantage of all of the development effort spent on robustness, as well as the all-important
experience of having done it all before.
Recommended Transition Plan
Phased
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* Less risky to outsource
Remove Technical Barriers
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* Technically complex Fast
* High degree of control required Phased
* Ties up lots of PMD revenue
Time (est. 3-4 years)
Figure 5.2: Recommended Transition Plan Illustration
2 Cost/Benefit
It must first be noted that the primary benefit of the approach, and in outsourcing
hardware handling in general, is not the labor savings that will result. Rather, the primary benefit
is in the process itself, in the cleaning and organization of products and processes that HP must
undertake to accommodate the outsourcing. The direct cost savings are not entirely clear, but
they are not likely to make a huge impact in HP's bottom line. However, the strategic leap to
new market structures and the management focus that outsourcing allow may make all the
difference in PMD's long term profitability.
Timing
The total time to complete the recommended transition will be substantial compared to a
single-group implementation or one that is less phased. Each sub-project and phase will take
time, which gives PMD's competition opportunities to catch up. There are two reasons why the
recommendation takes so long - HP has a good lead over its competitors, and HP shouldn't
expect to move any faster.
According to sources both internal and external to PMD (such as the trade press) HP's
patient data management products are significantly ahead of the rest of the patient monitoring
market. PMD's new product announcements are consistently breaking new ground in terms of
functionality and use of industry standard hardware. As long as PMD does not stand idle for an
extended period of time, it can take the time it needs to do a comprehensive, controlled
implementation. Strong competitive pressures are some time away.
Of greater importance is the fact that the more relaxed timing will contribute to the
project's chances of success. HP's careful nature with respect to medical device manufacturing
will not support a project with a more aggressive timeline. To see this we can refer back to
Leonard-Barton (1992), introduced in Chapter 3.
Leonard-Barton's work on core competencies and core rigidities considered a number of
development and improvement projects undertaken by companies. She found that projects that
are not aligned with the organizations' core competencies are less likely to succeed. HP Medical
has long held competencies in maintaining careful, controlled processes that guarantee high-
quality medical devices. Any project that does not support that competency will find resistance
to the speed of change, a core rigidity.
The new sourcing implementation is aligned with the future direction of PMD, but it also
is trying to shift some of the competencies currently in evidence. It supports competence in
software design and installation processes, but works to change the notion that HP must have
complete physical control over the product to ensure a quality result. This partial alignment with
existing competencies is the strength and weakness of the project. As such, it requires that HP
take the implementation at a reasonable pace, and that PMD's management show unqualified
support for the goals of the implementation.
Difficulty and Risk
No implementation can be undertaken without some level of risk. The only apparently
riskless choice for PMD is complete inaction, and that choice would eventually prove to be the
most dangerous. The primary risks in the recommended approach are in delays. The timeframe
is already stretched; a lack of urgency could reduce pressure on the development tasks required
to make the group B products modular and outsourceable. However, this risk can be mitigated
by a fixed schedule. Also, it is not as severe a risk as that of problems arising in a faster
implementation. The most threatening risks, those of product shortages or quality issues, are
better controlled by the careful implementation.
By beginning to move some products now, HP will have some success quickly, helping
make later transitions easier. Frequently organizations that recognize the importance of a major
change to operations have problems just getting the process started. The recommended approach
makes it easy to begin the process, and to continue the process once under way. Provided HP
keeps abreast of market changes and does not allow the implementation to take longer than its
strategic lead will allow, the approach minimizes failure risk.
Cost
Some process and support costs will increase during the transition period. The two large
product groupings alone would necessitate duplication of support processes within and outside
HP. The phased implementations for each group will force PMD to develop interim processes
that will be in use for only a short time. Some of the interim steps may have only a small number
of products processed in certain ways, which may not provide an efficient scale.
The cost increases will be only temporary, and will be clearly understood to be an
interim cost as HP transitions to an eventual supply chain structure that will cost less over the
long term, both directly and in terms of management focus. The costs of the implementation can
be viewed as an investment in long-term market management and profitability.
3 Preconditions
There are a number of changes that PMD must make if it hopes to be successful
implementing the recommended approach to its supply chain. They are primarily organizational;
the division must structure itself around future competencies. To the extent that the
preconditions are technical, they require that the organization set these technical issues as
priorities, and measure people accordingly.
Technical Issues
PMD's development efforts must focus on resolving the technical barriers to
outsourcing. Development tends to address marketing concerns before manufacturing concerns.
This is good policy in the short term. However PMD is facing an important (though not yet
urgent) task - that of providing unbundled software solutions within the next few years.
Manufacturing challenges will become very urgent if a competitor launches a "shrink-wrapped"
off-the-shelf patient monitoring solution, while PMD is still adding new functionality to software
that is tied to complicated manufacturing handling of hardware. Working to outsource hardware
handling is a practical step toward that unbundled solution.
There are several technical barriers that must be addressed:
* PMD must continue to standardize and to reduce the number of different operating
systems, hardware platforms, and network standards used in its products. This will keep
the hardware inventory management task from being needlessly complicated for a
supplier or for HP.
* Software products must be robust to the hardware they run on. Different brands and lots
of hardware should all be expected to work properly with PMD's software, provided it all
meets clear specifications. HP must also continue to build its skills in writing clear desk-
specifications for hardware capabilities.
* Software installation processes must be made consistent, unambiguous, and simple.
Although there is no reason why a third-party integrator shouldn't be able to follow more
complicated procedures, HP will cut costs and risks by making the software easy to
install, and hard to install improperly. Simpler installation procedures will enable HP to
spend less effort on ensuring that the processes are being followed properly, making
outsourcing more effective. Moreover, when the day comes that HP is trusting the
customer to install his own software, fool-proof processes are a must.
Eventually PMD's software products must be able to investigate the hardware on which
they are loaded, to ensure that the capabilities of the hardware are adequate for complete, safe
software functioning. Until software is being installed directly by the customer this is not
necessary, but installation and testing processes will be much simpler if this capability is
designed into the software earlier.
Organizational Issues
There are several less technical changes that HP must make for an outsourcing
implementation to be successful. Manufacturing and customer management processes must be
cleaned up, and PMD's vision must be clearly articulated in association with its sourcing
strategy.
PMD's processes and process controls must be cleaned up so that they no longer rely on
HP physically handling products. Good manufacturing practices require that HP track a number
of pieces of information about the medical devices it manufactures. The information
identification, recording, tracking, storing, and verification is currently attached to the product
physically. Often customer order tracking documentation travels with the product itself. HP has
grown accustomed to having the product in house, and some processes rely on being able to see
or get to the product during its manufacture. These processes must be changed so that the
physical product and the information about it are separated. When a contractor is integrating
software and hardware, it will still be HP's responsibility to maintain product and customer order
information, and processes must accommodate that.
At a higher level, HP Medical must overcome a long-standing reluctance to share control
and responsibilities with partners. HP knows that on its own it can manage medical device
manufacturing, and all of the associated process controls. Because cost and capacity constraints
have rarely plagued PMD, it has rarely felt the need to risk sharing responsibility with less
directly controlled partner. This is a fear that PMD must overcome. PMD must also develop a
greater general understanding of the regulatory implications and requirements in outsourcing, so
that they can be properly handled.
HP must develop and gain internal buy-in to a new vision of its core activities. The top-
down message must be that certain processes (such as hardware handling) are simply not in
PMD's core competencies, and that HP would be better off moving them outside. Without this
being fully understood, inertia and conservatism will set in. For example, consider the division
of products for the implementation. The selecting of which products are in group A versus group
B will probably entail some difficulty. Most people charged with managing product
manufacturing will tend to imagine that their products should be in group B, due to the
complexity they see in everyday management. If there is no strong feeling within PMD that
outsourcing is the desired direction for its products, then there will be no impetus to volunteer
one's product to be a trailblazer in the outsourcing implementation.
Finally, throughout the outsourcing process PMD must keep close watch over the market
and its competitors, to ensure that HP retains its lead. Customers may expect unbundled
software solutions faster than PMD has expected. Or, if competitors begin making advances on
HP's leadership position, perhaps by offering more modular software products in HP's market
space, then HP must adjust accordingly. In that case, the more leisurely recommended approach
will have to be scrapped for a more aggressive implementation and development effort. By the
time that could happen, PMD will have made some progress and will have some outsourcing
experience. It should be more able to make an aggressive leap, and the market pressure should
help HP focus on a tighter schedule.
4 Partner Considerations
The right partners are essential for HP's outsourcing effort to succeed. The two primary
things that the partner brings to the relationship are cost savings and relief to HP's leadership
from having to manage the processes the partner takes on. How well those two things are
delivered to HP will depend on how well it fits with HP, and the level of trust HP has in the
partner.
In a survey of automotive industry executives from suppliers, original equipment
manufacturers (OEMs), and trade associations, Cross and Gordon (1995) found that the most
important characteristic in an outsourcing partnership is trust. In the automotive industry, all
players recognize their interdependence. As outsourcing relationships grow tighter and more
intricate, and OEMs contract with fewer suppliers, trust only becomes more important. Although
medical device manufacturing has special concerns, it is clear that trust must be at least as
important there as in the auto industry.
There are many different kinds of potential outsourcing partners, from labor-only shops to
full design-through-shipment operations. It's important to find a provider that matches PMD's
requirements. Hilvers and Mucha (1993) describe several attributes that will be important for
PMD to consider it its fit with its providers:
* Service mix - PMD will likely want a partner to help with development and optimization
of integration and software load procedures initially. It will definitely want inventory
purchasing and management services and configuration to customer orders. This points
toward a fairly full-service outsourcer. PMD will probably want a partner that is willing
to share its cost structure and collaborate on improvements, for a share of the cost
advantage.
* Technology level - PMD's products use some very advanced hardware, and the partner
must be able to manage that. However, volumes are fairly low, so technology oriented at
extremely high throughput is not necessary.
* Quality system - The partner must be certifiable as a medical device manufacturer, and
must reliably follow established procedures for device manufacture and testing.
* Preferred manufacturing volumes - PMD's small volumes make its products
inappropriate for some of the largest contractors. However, PMD requires adequate
capacity to handle some level of irregularity in its production schedule.
The most important of these fits for PMD will be the quality system, because of PMD's tight
requirements in medical device manufacture. Particularly as PMD is still working out the
software/hardware dependence issues, it is imperative that the provider have quality of products
and processes as a top concern. HP must be able to rely on the provider to follow processes as
designed, every time. A culture dedicated to quality should be a basic requirement for PMD to
have any trust in the provider.
HP's relationship with its providers, based on the discussion regarding PMD's core
competencies, should be expected to be long-term. Rather than leaning hard on outsourcing
providers and re-bidding its contracts every six months, HP must approach the vendors with a
problem-solving attitude and one which supports the provider's right to make a living. Only in
that way can HP develop mutual trust with its providers and realize strategic gains from
outsourcing.
At the same time, HP must not lose its capabilities for developing integration processes
and controlling medical device manufacturing. Integration of hardware and software should
become a commodity service, if HP develops robust software. However, development of
integration processes and controls must be understood by PMD or HP will have become
dependent on its suppliers for knowledge in a key capability. HP cannot trust its suppliers to the
point that it becomes complacent itself.
5 Potential Implementation Program
This program is not a recommendation, but merely an example of a transition plan that
can get HP through the implementation within five years. Note that this work must be
considered within the context of PMD's other products and their respective strategies.
Segment Time Estimate
Transition Group A / Remove Technical Barriers 3-4 years
Re-orient R&D effort 6 months
* Establish and monitor metrics to evaluate robustness of software;
rank these metrics at least as highly as those measuring timely
delivery of new functionality in products.
* Initiate platform rationalization to reduce platforms and operating
systems used.
* Require desk hardware specifications be written for all new
software products (whether or not additional hardware controls are
required.)
Establish a United States merging capability 1 year
* Set up HP warehousing and shipping facility distinct from the
factory.
* Ship all completed PMD product to the facility.
* Procure Group A peripherals and network components directly into
that facility, so that PMD no longer physically handles them.
* Merge and ship consolidated customer orders from the facility.
* Establish independent order management processes through the
facility.
* Turn over management of shipments from the facility over to
sourcing partner. (Retain ownership of inventory)
Begin the process of eliminating the need for special hardware controls for 3 years
integral products (Group B) (concurrent with
* Test products with a variety of hardware that meet the desk Group A
specifications, rather than only with the specified hardware. activities)
* Simplify test and installation processes for products that are
currently integral.
* Decrease lot sizes (and increase order frequency) of hardware, so
that variety of incoming hardware increases and problems are
uncovered before products are outsourced.
* Restructure products to isolate technically troublesome components.
Outsource procurement for peripherals and network components of 6 months
modular products (Group A)
* Establish demand management processes for these components
within the merging facility.
* Transfer operation of the processes to the partner within the facility.
* Transfer ownership of managed inventory to the partner.
Outsource integration of hardware and software for Group A products 1 year
* Establish software delivery and version control processes.
* Establish integration capability and processes within
logistics/merging facility, managed by HP.
* Transfer management of integration processes to partner.
Complete elimination of hardware controls and modularization for Group B 6 months
products
* Transfer all test processes to integration stage.
* Eliminate lot controls over hardware.
* Expand desk specifications to allow greater freedom for hardware
sourcing (various brands and models).
Begin developing fully unbundled (software only) products within Group 1 year
A.
* Develop hardware test processes that can be performed by software
during installation.
* Change software installation so that configuration to customer
specifications can be managed either prior to software shipment or
by codes provided to the customer based on the order.
* Simplify installation processes for customer use.
Transition Group B - 1 year
Establish manufacturing capability for Group B products at partner 6 months
* Refine software delivery and version control processes.
* Build supplier competence in sourcing hardware based on desk
specifications.
* Initiate concurrent processes for Group B products at HP and
partner.
Over time, re-allocate HP internal manufacturing capacity to other products 6 months
(sensors, bedside monitors, etc.) effectively transitioning Group B products
to partner.
Begin developing fully unbundled (software only) products within Group 6 months
B. (assuming Group
* Develop hardware test processes that can be performed by software A products already
during installation. done)
* Change software installation so that configuration to customer
specifications can be managed either prior to software shipment or
by codes provided to the customer based on the order.
* Simplify installation processes for customer use.
The tasks are generally cross-functional in nature. As many of these tasks as possible
should be done concurrently, to maximize speed while minimizing risks.
6 Conclusion
Hewlett-Packard is a company known for its emergent formulation of strategy, in that it
takes stock of market conditions and its internal capabilities and steers the company toward new
products and capabilities that ensure future profitability. Such strategy formulation has been a
goal of this thesis.
The Patient Monitoring Division is positioned at the top of its market. It realizes that the
market for its patient data management products will change, and PMD must change with it.
Eventually, customers will demand, and competitors will offer, software solutions that are not
dependent on a particular hardware platform, or even on who does the installation. PMD must
have products and processes to support customer requirements.
The recommendations in this paper form a manageable path for PMD to follow in
preparation for the market environment of the future. The leap from today's situation to
unbundled software is too great to make without stepping stones. Outsourcing hardware
handling is a set of steps that address most of the current difficulties with offering unbundled
software solutions. Furthermore, whatever approach it takes, by the time HP offers unbundled
patient data management solutions, it will have eliminated any special value in HP's handling of
hardware, so outsourcing will have been an efficient path.
These recommendations cannot be simply taken and implemented directly. They must
be worked into an overall strategy for all of PMD's products, not just patient data management
solutions. More importantly, they must be organic, constantly updated to account for changing
market and internal realities. However, it is hoped that they will provide a starting point for
PMD's emergent product strategy for the next century.
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Appendix 1: PC Supply Chain Cost Model
Note: This model provided much of the insight that became my arguments. There were two
specific versions of the model and a generic version designed to be adapted to any of HP's PC-
based products. Due to the proprietary nature of the detailed data, the detail of the model is not
included here.
Problem Statement
PMD has multiple alternatives available to it for sourcing and integrating PCs for its
products. PMD will not select a single supply chain for all of its products, but it needs a way to
evaluate candidate supply chains and select a primary process for handling most of its products.
PMD will not make these decisions based on cost alone, but it needs to be able to analyze the
structural cost differences between supply chains as part of a larger analysis initiative.
For one particular product line, PMD is considering five different supply chain
structures, illustrated below in figure A1.1.
Integrated PC Product Supply Chain Alternatives
Figure Al.1: Integrated PC Product Supply Chain Alternatives
PMD must evaluate the cost differences within these supply chains during the design
phase of the product, so that it can select a supply chain to be implemented and fine-tuned during
the production ramp of the product. The goals of the model are to:
* Develop a model of the cost structures in a PC supply chain
* Investigate the comparative costs associated with each of the worldwide supply chain
alternatives
* Facilitate selection of a supply chain through cost information as well as service and other
considerations
* Develop and document a generic model for evaluation and selection of configured
component supply chains.
Analysis Methodology
The model is based on a generic unit of the supply chain, called a "process step". Each
step must receive inputs and perform the process. Outputs from the process are simply the inputs
to the next process. Costs in the supply chain can be divided into:
* Process costs,
* Process management (or support) costs, and
* Boundary costs, those costs incurred because processes are performed by multiple
partners.
This division of supply chain costs is illustrated in Figure A1.2.
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Figure A1.2: A Process Step
Each process step can be performed by any partner. However, the boundary costs for the
inputs to a process step will probably be substantially higher when the step is performed by a
different entity. Transportation costs will be higher if the partner is distant. Incoming inspection
costs will likely only occur during a transfer between partners. (Note that process control
inspection is considered to be a process cost.) Inventory holding will likely be greater, to
account for communication and transportation delay and uncertainty. And certainly relationship
management costs are substantially higher with additional partners.
The model, implemented in spreadsheet form using Lotus 1-2-3, aggregates all of the
costs in the supply chain across all process steps from building PCs through shipment to the
customer, and divides them by the cost categories described above. It would not be helpful for a
comparison model to compare every process step individually, because the supply chains make
trade-offs designed to minimize total rather than individual costs. Also, the comparison was
made for early-stage planning, so detailed process step cost information was not available for all
individual steps.
Estimates of real supply chain costs were made from within HP rather than basing the
model on quotes from potential partners. This was to avoid bias from partner quotes that would
be unprofitably low in an effort for the partner to gain HP's business, which might be substantial.
The assumption was made that partners would have to recoup their initial losses eventually, and
that over time gains or losses in total supply chain efficiency will have to be shared amongst all
partners.
Two further assumptions were made. First, it was assumed that homogeneous lot
verification would not be required. This was reasonable because the costs of lot verification
dwarf many of the other costs involved, apply to all five supply chains, and are expected to be
eliminated by HP's development teams eventually. Also, costs were estimated subject to the
constraint that PMD's on-time delivery rates must be maintained, and that product quality must
be at least as good as it is currently. Where tradeoffs between service or quality and cost were
inevitable, they were made at the expense of cost.
Costs were estimated based on a number of sources, including existing costing
documentation for earlier versions of the product, activity-based costing analysis performed by
HP's manufacturing organization, and interviews with HP engineers and managers. In cases
where existing data was used, it was re-classified in terms of the new model, and updated or
extrapolated where appropriate.
Results
Although detailed costs are proprietary to HP, the cost results are summarized in figure
Al.3. Note that for supply chains 1 and 2, the building of PCs is considered part of material cost,
while for supply chains 3-5, it is part of process cost. Supply chain 1 is HP's current supply
chain for earlier products of the same type as that under consideration. Supply chains 2 and 4 are
more expensive, by approximately 4% and 5%, respectively. Supply chains 3 and 5 are less
expensive, by approximately 5% and 7%, respectively.
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Figure A1.3: Cost of PC-Based Product across Supply Chain Alternatives
Material cost is a very large part of total cost. This makes total costs very sensitive to
small percentage variations in material costs. The third party in supply chain 2 must mark up
material that it handles, in order to make up its share of boundary costs and its own internal
support costs. Thus supply chain 2 is the most expensive; it appears to be so from material costs,
but in reality it is the increased boundary costs, as well as the necessity for several partners to
show profit from their parts of the supply chain.
Scale also had a large effect on costs. Supply chain 4 is the most expensive, primarily
because it would involve assembly of hardware without efficient scale. The volume of PCs that
would pass through this process is too small to efficiently support the management of PC
engineering and process control. The other supply chains spread large fixed process and process
management costs over much larger volumes of PCs.
Conclusions
Several key learnings came from the cost modeling, including:
Because transportation and inventory holding costs are so small compared to material
costs for these products, it is imperative to focus on controlling material costs while
investigating supply chain changes, rather than primarily on inventory or transportation
reductions.
* Eliminating stages in the supply chain reduces boundary costs, which are generally not
value-added. This is true as long as every process is performed by a partner that has a
minimum efficient scale. PC assembly is the process with the largest minimum efficient
scale.
* If PMD can eliminate the need for products to pass through its facilities at all, it may be
able to improve the responsiveness and cost of the supply chain.
The above notwithstanding, the differences in estimated costs are certainly within the
margin of error of the estimation techniques. This means that PMD should consider performing
more detailed analysis. Furthermore, gross margins on these products are such that these
differences in cost are not particularly substantial when considered against the products' selling
prices. Thus PMD should consider supply chain changes more from a strategic than a cost
perspective. Changes to PMD's product supply chains that actually increase costs could be small
investments for significant performance and strategic gains in PMD's marketplace.
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